RxDoctor Payments Data

Charles Page, MD

General Surgery · Nacogdoches, TXNPI 1437104585

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Johnson & Johnson at 32.7% of the total. Reporting peaked in 2023 at $72 and has fallen 70.2% since, to $21 in 2025.

$196in general payments, 2019–2025

Across 10 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$64
  • Braintree Laboratories, Inc.$40
  • KCI USA, Inc.$37
  • Biowound Solutions, Inc.$21
  • Covidien LP$21
  • Innocoll Pharmaceuticals Limited$13

What the payments were for

  • Food & beverage$196100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson3$64
Braintree Laboratories, Inc.2$40
KCI USA, Inc.2$37
Biowound Solutions, Inc.1$21
Covidien LP1$21
Innocoll Pharmaceuticals Limited1$13

How this compares

$196 in reported general payments places this provider in the 65th percentile of 61 general surgery providers in Texas.

See all general surgery providers in Texas

Medicare billing

Part B allowed, 2024
$177,263
Medicare patients
269
Services billed
1,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SutabSod Sulf/Pot Chloride/Mag Sulf43$6,849
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates106$6,691
Lubiprostone34$4,038
Omeprazole137$1,811
Colesevelam Hcl28$1,700
Famotidine125$1,379
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen64$598
Pantoprazole Sodium50$416
Ondansetron Hcl67$312
Sucralfate15$269
Anastrozole12$140
Ciprofloxacin Hcl19$135
Procto-Med HcHydrocortisone14$113
Acetaminophen-CodeineAcetaminophen With Codeine15$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Braintree Laboratories, Inc.Sutab$40$6,84943 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 61 general surgery providers in Texas.

Other general surgery in Nacogdoches

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →